This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): 10% Caprylate/Chromatography Purified, Gammaked, IGIV-C, Immune Globulin SC [Human], Kedrion IVIG 10%, TAL-05-0002
Description: BioMedTracker has a separate drug profile page for the subcutaneous formulation: Gamunex (SQ).
Gamunex is an immune globulin intravenous [Human], 10% Caprylate/Chromatography Purified (IGIV-C) therapy that contains antibodies purified from the donated blood plasma of thousands of people.
Talecris and Bayer
In April 2005, Bayer confirmed that it has completed its previously announcedtransaction to contribute the assets of its worldwide plasma products business to Talecris Biotherapeutics. The overall transactionvolume amounts to approximately US $590 million (approximately EUR 450 million), including cash, a 10 percent equity interest in TalecrisBiotherapeutics Holdings, retention of selected working capital items, and contingent payments of up to US $60 million.
All plasma activities in the United States were transferred to Talecris. In most other countries in which Bayer has been distributing plasma products, Bayer companies will continue todistribute plasma products on behalf of Talecris. Bayer and Talecris also have entered into several service and supply arrangements.
Grifols and Talecris
In June 2010, Grifols and Talecris announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination...See full deal structure in Biomedtracker
Partners: Kedrion S.p.A.
Gamunex (IV) News
Pink Sheet Bayer Gamunex approved
Additional information available to subscribers only: